Global GM1 Gangliosidosis Market, By Type (Classic Infantile, Juvenile, Adult), Diagnosis (Enzyme Analysis, Molecular Genetic Testing, Beta-Galactosidase Activity), Treatment (Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy), End-User (Research Institutes, Hospitals, Others), Distribution Channel (Hospitals, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global GM1 Gangliosidosis Market
The GM1 gangliosidosis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 26.50% in the above mentioned research forecast period. Ongoing research and products under clinical trials are the factors for the growth of the GM1 gangliosidosis market.
For instance,
- Passage Bio product PBGM01 is under clinical trial which is used for the treatment of infantile GM1 gangliosidosis. It will be used as a single dose of PBGM01 by intra-cisterna magna injection. This innovative product uses the next-generation AAVhu68 viral vector for the delivery of modified DNA encoding the b-gal enzyme to patient's cells. The main motive behind the designing the innovative product is to increase the levels of the b-gal enzyme in central nervous system and the peripheral nervous system.
GM1 gangliosidosis is considered as an inherited disorder which is responsible for destroying the nerve cells that is neurons present in brain and spinal cord. This disease is characterized on the basis of age group of the population and the severity differs according to their age. It is caused by the mutations in the GLB1 gene and deficiency of enzyme can lead to accumulation of gangliosides in a toxic level in the body tissues especially in central nervous system.
The most common type of GM1 gangliosidosis is type 1 (infantile GM1 gangliosidosis). The prevalence at birth is approximately 1:100,000 to 200,000 live births. High prevalence and increase in infantile population worldwide can increase the GM1 gangliosidosis market growth. In addition, initiatives taken by the market players to develop novel treatment for the disease can also increase the GM1 gangliosidosis market growth. For instance, in February 2017, Lysogene has announced that they have received orphan drug designation for one of their product LYS-GM101 which is used for the treatment of GM1 gangliosidosis. Increase in funding provided by the different organizations to support the treatment of GM1 gangliosidosis can increase the GM1 gangliosidosis market growth. For instance, Cure GM1 Foundation involved in providing the funding for the population suffering from GM1 gangliosidosis. Lack of availability of specific treatment and high cost of available treatment such as gene therapy or replacement therapy may hamper the GM1 gangliosidosis market growth.
This GM1 gangliosidosis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the GM1 gangliosidosis market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
GM1 Gangliosidosis Market Scope and Market Size
The GM1 gangliosidosis market is segmented on the basis of type, diagnosis, treatment, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the GM1 gangliosidosis market is segmented into classic infantile, juvenile and adult.
- On the basis of diagnosis, the GM1 gangliosidosis market is segmented into enzyme analysis, molecular genetic testing and beta-galactosidase activity.
- On the basis of treatment, the GM1 gangliosidosis market is segmented into anticonvulsants, bone marrow transplantation, cord-blood hematopoietic stem-cell transplantation, enzyme replacement and gene therapy.
- On the basis of end-user, the GM1 gangliosidosis market is segmented to research institutes, hospitals and others.
- On the basis of distribution channel, the GM1 gangliosidosis market is segmented into hospitals and others.
Global GM1 Gangliosidosis Market Country Level Analysis
Global GM1 gangliosidosis market is analysed and market size information is provided by country, type, diagnosis, treatment, end-user and distribution channel as referenced above.
The countries covered in the GM1 gangliosidosis market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America along with South America accounts the largest market share because of increased number of patients suffering from GM1 gangliosidosis and increasing healthcare expenditure. Asia-Pacific also shares a market share due to increase in healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The GM1 gangliosidosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to GM1 gangliosidosis market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the GM1 gangliosidosis market in the growth period.
Competitive Landscape and Global GM1 Gangliosidosis Market Share Analysis
The GM1 gangliosidosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global GM1 gangliosidosis market.
The major players covered in the global GM1 gangliosidosis market report are Axovant Gene Therapies Ltd. and Passage Bio and Lysogene among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-